1887

Abstract

The molecular and antigenic properties of a Sabin-like type 2 poliovirus, isolated from the stool samples of a 2-year-old agammaglobulinaemic child who developed paralysis 1 year after receiving the third dose of oral poliovirus vaccine, were analysed. The virus revealed 0·88 % genome variation in the VP1 region compared with the standard reference strain, compatible with replication of the virus in the intestine over approximately 1 year. The typical mutations in the 5′NCR and VP1 associated with reversion to neurovirulence for Sabin type 2 poliovirus were found. Despite this, the virus was characterized by both PCR and ELISA tests as Sabin-like and showed temperature sensitivity and neurovirulence in transgenic mice typical of the Sabin type 2 vaccine strain. Gammaglobulin replacement therapy led rapidly to virus clearance, which, when combined with treatment with the antiviral drug pleconaril, stopped virus excretion; no further virus shedding occurred. This is the first case of poliomyelitis and long-term excretion from an immunodeficient patient to be reported in Italy through the active ‘Acute Flaccid Paralysis' surveillance system.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.18974-0
2003-05-01
2020-01-18
Loading full text...

Full text loading...

/deliver/fulltext/jgv/84/5/vir841215.html?itemId=/content/journal/jgv/10.1099/vir.0.18974-0&mimeType=html&fmt=ahah

References

  1. Bellmunt, A., May, G., Zell, R., Pring-Akerblom, P., Verhagen, W. & Heim, A. ( 1999; ). Evolution of poliovirus type I during 5·5 years of prolonged enteral replication in an immunodeficient patient. Virology 265, 178–184.[CrossRef]
    [Google Scholar]
  2. Bouchard, M. J., Lam, D. H. & Racaniello, V. R. ( 1995; ). Determinants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin vaccine. J Virol 69, 4972–4978.
    [Google Scholar]
  3. Buttinelli, G., Ruggeri, F. M., Marturano, J., Novello, F., Donati, V. & Fiore, L. ( 2001; ). Antigenic sites of poliovirus type 3 eliciting IgA monoclonal antibodies in orally immunized mice. Virology 281, 265–271.[CrossRef]
    [Google Scholar]
  4. CDC ( 2002a; ). Acute flaccid paralysis associated with circulating vaccine-derived poliovirus: Philippines 2001. JAMA 287, 311.[CrossRef]
    [Google Scholar]
  5. CDC ( 2002b; ). Public health dispatch: poliomyelitis, Madagascar, 2002. MMWR Morb Mortal Wkly Rep 51, 622.
    [Google Scholar]
  6. Christodoulou, C., Colbère-Garapin, F., Macadam, A., Taffs, L. F., Marsden, P., Minor, P. & Horaud, F. ( 1990; ). Mapping of mutations associated with neurovirulence in monkeys infected with Sabin poliovirus revertants selected at high temperature. J Virol 64, 4922–4929.
    [Google Scholar]
  7. Crainic, R., Blondel, B. & Horaud, F. ( 1984; ). Antigenic variation of poliovirus studied by means of monoclonal antibodies. Rev Infect Dis 6 (Suppl. 2), S535–S539.[CrossRef]
    [Google Scholar]
  8. Di Lonardo, A., Buttinelli, G., Amato, C., Novello, F., Ridolfi, B. & Fiore, L. ( 2002; ). Rapid methods for identification of poliovirus isolates and determination of polio neutralizing antibody titers in human sera. J Virol Methods 101, 189–196.[CrossRef]
    [Google Scholar]
  9. Domingo, E. & Holland, J. J. ( 1997; ). RNA virus mutations and fitness for survival. Annu Rev Microbiol 51, 151–178.[CrossRef]
    [Google Scholar]
  10. Ehrenfeld, E. & Semler, B. L. ( 1995; ). Anatomy of the poliovirus 5′ NCR. Curr Top Microbiol Immunol 203, 165–179.
    [Google Scholar]
  11. Equestre, M., Genovese, D., Cavalieri, F., Fiore, L., Santoro, R. & Perez Bercoff, R. ( 1991; ). Identification of a consistent pattern of mutations in neurovirulent variants derived from the Sabin vaccine strain of poliovirus type 2. J Virol 65, 2707–2710.
    [Google Scholar]
  12. Finney, D. J. ( 1971; ). Statistical aspects of monitoring for dangers in drug therapy. Methods Inf Med 10, 1–8.
    [Google Scholar]
  13. Fiore, L., Novello, F., Simeoni, P., Amato, C., Vellucci, L., De Stefano, D., Grandolfo, M. E., Luzzi, I. and the AFP Study Group ( 1999; ). Surveillance of acute flaccid paralysis in Italy: 1996–97. Eur J Epidemiol 15, 757–763.[CrossRef]
    [Google Scholar]
  14. Fiore, L., Novello, F., Simeoni, P. & 7 other authors and the Group for the Study of AFP ( 2000; ). Epidemiology of acute flaccid paralysis in Italy: 1996–98. Ann Ig 12, 99–110 (in Italian).
    [Google Scholar]
  15. Georgescu, M. M., Balanant, J., Macadam, A., Otelea, D., Combiescu, M., Combiescu, A. A., Crainic, R. & Delpeyroux, F. ( 1997; ). Evolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis. J Virol 71, 7758–7768.
    [Google Scholar]
  16. Hull, H. F., Birmingham, M. E., Melgaard, B. & Lee, J. W. ( 1997; ). Progress towards global polio eradication. J Infect Dis 175 (Suppl. 1), S4–S9.[CrossRef]
    [Google Scholar]
  17. Kew, O. M., Mulders, M. N., Lipskaya, G., da Silva, E. E. & Pallansch, M. A. ( 1995; ). Molecular epidemiology of polioviruses. Semin Virol 6, 401–414.[CrossRef]
    [Google Scholar]
  18. Kew, O. M., Sutter, R. W., Nottay, B. K., McDonough, M. J., Prevots, D. R., Quick, L. & Pallansch, M. A. ( 1998; ). Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. J Clin Microbiol 36, 2893–2899.
    [Google Scholar]
  19. Kew, O. M., Morris-Glasgow, V., Landaverde, M. & 21 other authors ( 2002; ). Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 296, 356–359.[CrossRef]
    [Google Scholar]
  20. Kilpatrick, D. R., Nottay, B., Yang, C. F., Yang, S. J., Da Silva, E., Penaranda, S., Pallansch, M. A. & Kew, O. M. ( 1998; ). Serotype-specific identification of polioviruses by PCR using primers containing mixed-base or deoxyinosine residues at positions of codon degeneracy. J Clin Microbiol 36, 352–357.
    [Google Scholar]
  21. Koike, S., Taya, C., Kurata, T., Abe, S., Ise, I., Yonekawa, H. & Nomoto, A. ( 1991; ). Transgenic mice susceptible to poliovirus. Proc Natl Acad Sci U S A 88, 951–955.[CrossRef]
    [Google Scholar]
  22. Lentz, K. N., Smith, A. D., Geisler, S. C. & 9 other authors ( 1997; ). Structure of poliovirus type 2 Lansing complexed with antiviral agent SCH48973: comparison of the structural and biological properties of three poliovirus serotypes. Structure 5, 961–978.[CrossRef]
    [Google Scholar]
  23. Martin, J., Dunn, G., Hull, R., Patel, V. & Minor, P. D. ( 2000; ). Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion. J Virol 74, 3001–3010.[CrossRef]
    [Google Scholar]
  24. Martin, J., Samoilovich, E., Dunn, G. & 7 other authors ( 2002; ). Isolation of an intertypic poliovirus capsid recombinant from a child with vaccine-associated paralytic poliomyelitis. J Virol 76, 10921–10928.[CrossRef]
    [Google Scholar]
  25. McKinney, R. E., Jr, Katz S. L. & Wilfert, C. M. ( 1987; ). Chronic enteroviral meningoencephalitis in agammaglobulinemic patients. Rev Infect Dis 9, 334–356.[CrossRef]
    [Google Scholar]
  26. Minor, P. D. ( 1980; ). Comparative biochemical studies of type 3 poliovirus. J Virol 34, 73–84.
    [Google Scholar]
  27. Minor, P. D. ( 2001; ). Biosafety consequences of eradication of wild-type polioviruses. Lancet 358, 166–168.[CrossRef]
    [Google Scholar]
  28. Minor, P. D. & Dunn, G. ( 1988; ). The effect of sequences in the 5′ non-coding region on the replication of polioviruses in the human gut. J Gen Virol 69, 1091–1096.[CrossRef]
    [Google Scholar]
  29. Novello, F., Lombardi, F., Amato, C., Santoro, R., Fiore, L., Grandolfo, M. E. & Pasquini, P. ( 1987; ). Paralytic poliomyelitis in Italy (1981–85). Eur J Epidemiol 3, 54–60.[CrossRef]
    [Google Scholar]
  30. Pevear, D. C., Tull, T. M., Seipel, M. E. & Groarke, J. M. ( 1999; ). Activity of pleconaril against enteroviruses. Antimicrob Agents Chemother 43, 2109–2115.
    [Google Scholar]
  31. Pollard, S. R., Dunn, G., Cammack, N., Minor, P. D. & Almond, J. W. ( 1989; ). Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine. J Virol 63, 4949–4951.
    [Google Scholar]
  32. Rezapkin, G. V., Fan, L., Asher, D. M., Fibi, M. R., Dragunsky, E. M. & Chumakov, K. M. ( 1999; ). Mutations in Sabin 2 strain of poliovirus and stability of attenuation phenotype. Virology 258, 152–160.[CrossRef]
    [Google Scholar]
  33. Rotbart, H. A. ( 1999; ). Antiviral therapy for enteroviral infections. Ped Infect Dis J 18, 632–633.[CrossRef]
    [Google Scholar]
  34. Rotbart, H. A. & Webster, A. D. ( 2001; ). Treatment of potentially life-threatening enterovirus infections with pleconaril. Clin Infect Dis 32, 228–235.[CrossRef]
    [Google Scholar]
  35. Sabin, A. B. & Boulger, L. R. ( 1973; ). History of Sabin attenuated poliovirus oral live vaccine strains. J Biol Stand 1, 115–118.[CrossRef]
    [Google Scholar]
  36. Shulman, L. M., Manor, Y., Handsher, R. & 11 other authors ( 2000; ). Molecular and antigenic characterization of a highly evolved derivative of the type 2 oral poliovaccine strain isolated from sewage in Israel. J Clin Microbiol 38, 3729–3734.
    [Google Scholar]
  37. van der Avoort, H. G., Hull, B. P., Hovi, T., Pallansch, M. A., Kew, O. M., Crainic, R., Wood, D. J., Mulders, M. N. & van Loon, A. M. ( 1995; ). Comparative study of five methods for intratypic differentiation of polioviruses. J Clin Microbiol 33, 2562–2566.
    [Google Scholar]
  38. WHO ( 1997; ). Manual for the Virologic Investigation of Poliomyelitis. WHO/EPI/GEN/97. I. World Health Organization, Geneva, Switzerland.
  39. WHO ( 2001; ). Polio Laboratory Manual. World Health Organization, Geneva, Switzerland.
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.18974-0
Loading
/content/journal/jgv/10.1099/vir.0.18974-0
Loading

Data & Media loading...

Most cited articles

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error